Nagaraju Sarabu

Nagaraju Sarabu

Auto-generated profile, based on publicly available information

Nagaraju Sarabu

Medicine, University Hospitals, Cleveland, OH

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2019 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
KLKrista L Lentine
Krista L Lentine
FKFarrukh M. Koraishy
Farrukh M. Koraishy
NSNagaraju Sarabu
Nagaraju Sarabu
ANAbhijit S. Naik
Abhijit S. Naik
NLNgan N. Lam
Ngan N. Lam
MSMark A. Schnitzler
Mark A. Schnitzler

11 August 2018 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
ALAngela Liu
Angela Liu
KWKenneth J Woodside
Kenneth J Woodside
JAJoshua J. Augustine
Joshua J. Augustine
NSNagaraju Sarabu
Nagaraju Sarabu

22 September 2022 in Current Transplantation Reports
Verified
Journal Article
Open access
PDF file
KLKrista L Lentine
Krista L Lentine
NSNagaraju Sarabu
Nagaraju Sarabu
GMGwen McNatt
Gwen McNatt
RHRobert Howey
Robert Howey
RHRebecca Hays
Rebecca Hays
ATAndrea Tietjen
Andrea Tietjen
Purpose of Review: While living organ donor follow-up is mandated for 2 years in the USA, formal guidance on recovering associated costs of follow-up care is lacking. In this review, we discuss current billing practices of transplant programs for living kidney donor follow-up, and propose future directions for managing follow-up costs and supporting cost neutrality in donor care. Recent Findings: Living donors may incur costs and financial risks in the donation process, including travel, lost time from work, and dependent care. In addition, adherence to the Organ Procurement and Transplantation Network (OPTN) mandate for US transplant programs to submit 6-, 12-, and 24-month postdonation follow-up data to the national registry may incur out-of-pocket medical costs for donors. Notably, the Centers for Medicare and Medicaid Services (CMS) has explicitly disallowed transplant programs to bill routine, mandated follow-up costs to the organ acquisition cost center or to the recipient’s Medicare insurance. We conducted a survey of transplant staff in the USA (distributed October 22, 2020–March 15, 2021), which identified that the mechanisms for recovering or covering the costs of mandated routine postdonation follow-up at responding programs commonly include billing recipients’ private insurance (40%), while 41% bill recipients’ Medicare insurance. Many programs reported utilizing institutional allowancing (up to 50%), and some programs billed the organ acquisition cost center (25%). A small percentage (11%) reported billing donors or donors’ insurance. Summary: To maintain a high level of adherence to living donor follow-up without financially burdening donors, up-to-date resources are needed on handling routine donor follow-up costs in ways that are policy-compliant and effective for donors and programs. Development of a government-supported national living donor follow-up registry like the Living Donor Collective may provide solutions for aspects of postdonation follow-up, but requires transplant program commitment to register donors and donor candidates as well as donor engagement with follow-up outreach contacts after donation.

2 March 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
DNDavid K. Ngendahimana
David K. Ngendahimana
SDSalil V. Deo
Salil V. Deo
VSVarun Sundaram
Varun Sundaram
KLKrista L. Lentine
Krista L. Lentine
CHCharles A. Herzog
Charles A. Herzog
NSNagaraju Sarabu
Nagaraju Sarabu
Background: Limited literature exists that evaluated outcomes of kidney transplant–eligible patients who are having dialysis and who are undergoing valve replacement. Our main objective in this study was to compare mortality, reoperation, and bleeding episodes between bioprosthetic and mechanical valve procedures among kidney transplant–eligible patients who are having dialysis. Methods and Results: We studied 887 and 1925 dialysis patients from the United States Renal Data System, who underwent mitral valve replacement and aortic valve replacement (AVR) after being waitlisted for a kidney transplant (2000–2015), respectively. Time to death, time to reoperation, and time to bleeding requiring hospitalizations were compared separately for AVR and mitral valve replacement. Kaplan–Meier survival curves, Cox proportional hazards model for time to death, accelerated time to event model for time to reoperation, and counting process model for time to recurrent bleeding were used. There were no differences in mortality (hazard ratio [HR], 0.92; 95% CI, 0.77–1.09) or risk of reoperation or risk of significant bleeding events between bioprosthetic and mechanical mitral valve replacement. However, mechanical AVR was associated with a modestly significant less hazard of death (HR, 0.83; 95% CI, 0.74–0.94) compared with bioprosthetic AVR. There were no differences in time to reoperation, or time to significant bleeding events between bioprosthetic and mechanical AVR. Conclusions: For kidney transplant waitlisted patients who are on dialysis and who are undergoing surgical valve replacement, bioprosthetic and mechanical valves have comparable survival, reoperation rates, and bleeding episodes requiring hospitalizations at both mitral and aortic locations. These findings emphasize that an individualized informed decision is recommended when choosing the type of valve for this special group of patients having dialysis.


29 September 2021 in Kidney Medicine
Verified
Journal Article
Open access
NSNagaraju Sarabu
Nagaraju Sarabu
NSNicholas Schiltz
Nicholas Schiltz
KWKenneth J. Woodside
Kenneth J. Woodside
AHAnne M. Huml
Anne M. Huml
ASAshwini R. Sehgal
Ashwini R. Sehgal
DHDonald E. Hricik
Donald E. Hricik
The impact of prostate cancer on mortality in patients with end-stage kidney disease may be different from the general population. Prostate cancer may also delay the kidney transplant but has not been studied in a population-based cohort. We examined how prostate cancer influenced time to kidney transplant and death in a dialysis population. Retrospective population-based, risk-set propensity score–matched cohort study. Men, 40-79 years old, who were dialysis-dependent Medicare beneficiaries without prior documented prostate cancer, from the United States Renal Data System. Incident prostate cancer, identified using International Classification of Disease, Ninth Revision, Clinical Modification system diagnosis code 185. Time to kidney transplant and death. Propensity-based risk-set matching to reduce bias between cases and controls. Cox proportional hazards model for time to death, and Fine-Gray competing risk model for time to kidney transplant. Among a total of 588,478 male dialysis patients who met the eligibility criteria, 18,162 had claims for prostate cancer. After propensity-based risk-set matching, 15,554 pairs of prostate cancer cases and controls were identified. Among the matched pairs, survival rates were 76%, 48%, and 30% at 1, 3, and 5 years in the prostate cancer group, compared with 80%, 51%, and 33% in the control group, with relative mortality of 95%, 94%, and 91% respectively (log-rank test P < 0.001). Prostate cancer was associated with a 22% lower likelihood of kidney transplant (HR: 0.78; 95% CI: 0.72-0.85) and 11% higher likelihood of death (HR: 1.11; 95% CI: 1.08-1.14) compared with controls. Kidney transplant was associated with a 4-fold improvement in overall survival, both in patients with and without prostate cancer (HR: 0.20; 95% CI: 0.18-0.21). Retrospective registry study. Prostate cancer is associated with a modest increase in the risk of death and time to transplant in patients with end-stage kidney disease. Kidney transplant is associated with the same degree of survival benefit among those with pretransplant prostate cancer as those without.